Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
Speakers
Dave Ricks
— Eli Lilly Chair & CEO
Jim Cramer
— Host, Mad Money
Summary
Eli Lilly CEO David Ricks discusses the company's path to a $1 trillion market value, driven by obesity-drug innovation and a faster R&D model. He outlines several growth drivers: the upcoming oral obesity pill, manufacturing capacity, retatrutide and inflammation data, and a brain-disease pipeline. Ricks also explains why oral GLP-1s could significantly expand the obesity market over the next 3-4 years.
- David Ricks attributes Lilly's $1T valuation to innovation and focus on common diseases.
- Lilly expects an oral obesity pill launch later this year.
- Oral GLP-1s may expand the obesity market from roughly 10% penetration.
- Lilly has invested $50B in manufacturing, with most not yet online.
- Retatrutide Phase 3 data showed ~29% weight loss and knee-pain relief.
- Lilly is pursuing brain-disease indications like alcohol and opioid use disorders.
- Ricks discussed an AI collaboration with NVIDIA to model human biology.
Ideas
Innovation and catalysts support Eli Lilly.
David Ricks attributes Eli Lilly's $1 trillion market value to innovation, faster R&D, and a focus on large common diseases, especially obesity. He highlights multiple forward catalysts: a potential oral obesity pill launch later this year, retatrutide Phase 3 data by mid-year, manufacturing expansion, and long-term innovation outside obesity. This supports a positive long-term view on Eli Lilly.
Up Next
This CNBC video, published January 13, 2026, features Dave Ricks discussing LLY. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: Dave Ricks · Tickers: LLY